Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 18,744 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Prostate Cancer
Interventions: Two-Fraction Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: AMG 479, Everolimus, Panitumumab; Drug
Lead sponsor: Jeffrey Clarke; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain Tumor, Cancer
Interventions: Zotiraciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 99 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Jacksonville, Florida • Bethesda, Maryland

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod; Procedure · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Cisplatin, Etoposide, Veliparib, Placebo; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 428
States / cities: Loma Linda, California • Palo Alto, California • Aurora, Colorado + 279 more

Conditions: Gastrointestinal Adenocarcinomas
Interventions: MEDI-565; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Augusta, Georgia • Durham, North Carolina + 1 more

Conditions: Healthy Participants
Interventions: BMS-986421, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: ALXN2050, Fluconazole, Rifampin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV Infections
Interventions: Tenofovir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: ALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat; Genetic · Biological · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 11
States / cities: Gilbert, Arizona • Duarte, California • Palo Alto, California + 8 more

Conditions: Prostate Cancer
Interventions: Estramustine, Thalidomide, Paclitaxel (Taxol); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Tumor, Solid, Refractory Cancer
Interventions: TBX-3400; Biological
Lead sponsor: Taiga Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: SNX-5422; Drug
Lead sponsor: Esanex Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Augusta, Georgia • Hackensack, New Jersey + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CC100, Placebos; Drug
Lead sponsor: Chemigen, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Galveston, Texas • Houston, Texas

Conditions: Obesity
Interventions: ERX1000, Placebo; Drug
Lead sponsor: ERX Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rectal Cancer, Colo-rectal Cancer
Interventions: Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl); Drug · Radiation
Lead sponsor: George Albert Fisher; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bipolar Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 32
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more

Conditions: Rectal Neoplasms
Interventions: topotecan, radiation, surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Solid Tumors, Advanced Solid Tumors
Interventions: RO6870810; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 1 more

Conditions: Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions: conjugated estrogens, medroxyprogesterone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions: Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bridge Therapy, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Ultrasonographic Elastography; Biological · Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Central Nervous System Malignancies, Ependymoma
Interventions: 5-fluorouracil; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Month to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Enterotoxigenic E. Coli (ETEC) Infection
Interventions: ACE527 vaccine, Placebo vaccine; Biological
Lead sponsor: TD Vaccines A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Two Fraction Prostate SBRT With DIL SIB

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

A Study of PMPA in HIV-Infected Patients

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

BHV-7000 Open-Label Extension Bipolar Mania Study

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma

ACE527 Safety and Immunogenicity Study